2D QSAR, design, docking study and ADMET of some N-aryl derivatives concerning inhibitory activity against Alzheimer disease

Future Journal of Pharmaceutical Sciences - Tập 8 - Trang 1-14 - 2022
Abduljelil Ajala1, Adamu Uzairu1, Gideon A. Shallangwa1, Stephen E. Abechi1
1Department of Chemistry, Faculty of Physical Sciences, Ahmadu Bello University, Zaria, Nigeria

Tóm tắt

Alzheimer disease (AD) is an ailment that disturbs mainly people of old age. The fundamental remedial way to deal with AD depends on the utilization of AChEI. The design of new intense and particular AChEI is critical in drug discovery. In silico technique will be used to solve the above problem. A new method was established to discover novel agents with better biological activity against Alzheimer disease. A validated model was established in this research to predict the biological activities of some anti-Alzheimer compounds and to design new hypothetical drugs influenced with molecular properties in the derived model; ATS4i, MATS2e, SpMax7_BhS, Energy(HOMO) and Molecular Weight and showed good correlation R2 = 0.936, R2adj = 0.907, Q2cv = 0.88, LOF = 0.0154 and R2ext = 0.881. All the descriptors in the model were in good agreement with the 15 test set predicted values. Five compounds were designed using D35rm as a template with improved activity. The compounds have higher and better binding scores (− 10.1, − 9.4, − 9.3, − 9.1 and − 8.1 all in kcal/mol) than the approved drugs (Donepezil =  − 7.4 kcal/mol). As the outcome, every one of the selected and the designed compounds is created and improved as potential anti-Alzheimer agents. Despite this, the further test examines and in vivo investigations are recommended to assess the method of the activities and other pharmacological impacts on these compounds.

Tài liệu tham khảo

Salthouse TA (2004) What and when of cognitive aging. Curr Dir Psychol Sci 13(4):140–144

Association A (2015) 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement 11(3):332–384. https://doi.org/10.1016/j.jalz.2015.02.003

Cummings JL (2000) The role of cholinergic agents in the management of behavioural disturbances in Alzheimer’s disease. Int J Neuropsychopharmacol 3(SUPPL. 2):21–29

Huang LK, Chao SP, Hu CJ (2020) Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27:1–13

Verma N, Beretvas SN, Pascual B, Masdeu JC, Markey MK (2015) New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimer’s Res Ther 7(1):1–17

Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P et al (2010) Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr 22(3):346–372

Mehta D, Jackson R, Paul G, Shi J, Sabbagh M (2017) Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs 26(6):735–739. https://doi.org/10.1080/13543784.2017.1323868

Serafini MM, Catanzaro M, Rosini M, Racchi M, Lanni C (2017) Curcumin in Alzheimer’s disease: can we think to new strategies and perspectives for this molecule? Pharmacol Res 124:146–155. https://doi.org/10.1016/j.phrs.2017.08.004

Więckowska A, Kołaczkowski M, Bucki A, Godyń J, Marcinkowska M, Więckowski K et al (2016) Novel multi-target-directed ligands for Alzheimer’s disease: combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation. Eur J Med Chem 124:63–81. https://doi.org/10.1016/j.ejmech.2016.08.016

Skrzypek A, Matysiak J, Karpińska MM, Niewiadomy A (2013) Synthesis and anticholinesterase activities of novel 1,3,4-thiadiazole based compounds. J Enzyme Inhib Med Chem 28(4):816–823

Rossi E, Noberasco C, Picchi M, Di SM, Rossi A, Nurra L et al (2018) Complementary and integrative medicine to reduce adverse effects of anticancer therapy. J Altern Complement Med 24(9–10):933–941

Hung CL, Chen CC (2014) Computational approaches for drug discovery. Drug Dev Res 75(6):412–418

Macalino SJY, Gosu V, Hong S, Choi S (2015) Role of computer-aided drug design in modern drug discovery. Arch Pharm Res 38(9):1686–1701

Correa-Basurto J, Flores-Sandoval C, Marín-Cruz J, Rojo-Domínguez A, Espinoza-Fonseca LM, Trujillo-Ferrara JG (2007) Docking and quantum mechanic studies on cholinesterases and their inhibitors. Eur J Med Chem 42(1):10–19

Tong W, Hong H, Xie Q, Shi L, Fang H, Perkins R (2005) Assessing QSAR limitations—a regulatory perspective. Curr Comput Aided Drug Des 1(2):195–205

Taylor P, Ghafourian T, Cronin MTD (2015) The impact of variable selection on the modelling of oestrogenicity. SAR QSAR Environ Res 16:37–41

Duardo-sánchez A, Patlewicz G, López-díaz A (2008) Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr Top Med Chem 8:1666–1675

González-Díaz H, Vilar S, Santana L, Uriarte E (2007) Medicinal chemistry and bioinformatics—current trends in drugs discovery with networks topological indices. Curr Top Med Chem 7:1015–1029

Vilar S, Cozza G, Moro S (2008) Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 8:1555–1572

Morales A, Combes RD, Pérez M, Natália MDS (2008) Applications of 2D descriptors in drug design: a DRAGON tale. Curr Top Med Chem 8:1628–1655

Adedirin O, Uzairu A, Shallangwa GA, Abechi SE (2018) Computational studies on α-aminoacetamide derivatives with anticonvulsant activities. Beni-Suef Univ J Basic Appl Sci. 3:1–10. https://doi.org/10.1016/j.bjbas.2018.08.005

Shao Y, Molnar LF, Jung Y, Kussmann J, Ochsenfeld C, Brown ST et al (2006) Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys 8(27):3172–3191

Ambure P, Aher RB, Gajewicz A, Puzyn T, Roy K (2015) “NanoBRIDGES” software: open access tools to perform QSAR and nano-QSAR modeling. Chemom Intell Lab Syst 147:1–13. https://doi.org/10.1016/j.chemolab.2015.07.007

Tropsha A (2010) Best practices for QSAR model development, validation, and exploitation. Mol Inform 29(6–7):476–488

Khaled KF, Abdel-Shafi NS (2011) Quantitative structure and activity relationship modeling study of corrosion inhibitors: genetic function approximation and molecular dynamics simulation methods. Int J Electrochem Sci 6:4077–94. Available from www.electrochemsci.org

Arthur DE, Uzairu A, Mamza P, Abechi SE, Shallangwa G (2018) Insilico modelling of quantitative structure–activity relationship of pGI50 anticancer compounds on K-562 cell line. Cogent Chem 4(1):1–23. https://doi.org/10.1080/23312009.2018.1432520

Golbraikh A, Tropsha A (2002) Beware of q 2 ! J Mol Graph Modell 20:269–276

Afantitis A, Melagraki G, Sarimveis H, Igglessi-Markopoulou O, Kollias G (2009) A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. Eur J Med Chem 44(2):877–884

Jaworska J, Nikolova-Jeliazkova N, Aldenberg T (2005) QSAR applicability domain estimation by projection of the training set in descriptor space: a review. Altern Lab Anim 33:445–459

Ellison CM, Sherhod R, Cronin MTD, Enoch SJ, Madden JC, Judson PN (2011) Assessment of methods to define the applicability domain of structural alert models. J Chem Inf Model 51:975–985

Tropsha A, Golbraikh A (2007) Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharmaceut Des 13:3494–3504

Abdulfatai U, Uzairu A, Uba S, Shallangwa GA (2019) Molecular modelling and design of lubricant additives and their molecular dynamic simulations studies of diamond-like-carbon (DLC) and steel surface coating. Egypt J Pet 28(1):111–115. https://doi.org/10.1016/j.ejpe.2018.12.004

Ibrahim MT, Uzairu A, Shallangwa GA, Ibrahim A (2020) In-silico studies of some oxadiazoles derivatives as anti-diabetic compounds. J King Saud Univ Sci 32(1):423–432

Brooijmans N (2009) Chapter: Docking methods, ligand design, and validating data sets in the structural genomics era. In: Gu J, Bourne PE (eds) Structural bioinformatics. Wiley, New York, pp 635–663

Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:1–13. https://doi.org/10.1038/srep42717

Pires DEV, Blundell TL, Ascher DB (2015) pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066–4072

Matlock MK, Hughes TB, Dahlin JL, Swamidass SJ (2018) Modeling small-molecule reactivity identifies promiscuous bioactive compounds. J Chem Inf Model 58(8):1483–1500

Lipinski CA (2016) Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev 101:34–41. https://doi.org/10.1016/j.addr.2016.04.029

Hassan SSU, Zhang WD, Jin HZ, Basha SH, Priya SS (2022) In silico anti-inflammatory potential of guaiane dimers from Xylopia vielana targeting COX-2. J Biomol Struct Dyn 40(1):484–498. https://doi.org/10.1080/07391102.2020.1815579

Thông tin
Thông tin xuất bản

Future Journal of Pharmaceutical Sciences

Tập 8

1-14

Thông tin tác giả